Skip to content
207.878.2770mail@immucell.com
Immucell
Immediate Immunity™
Immucell
  • About ImmuCell
    • About ImmuCell
    • Our Purpose
    • Management and Directors
    • Career Opportunities
    • Contact Us
  • First Defense
    • Tri-Shield First Defense®
    • Manufacturing Facility Expansion
    • Manufacturing Facility Virtual Tour
    • Testimonials
  • Re-Tain
    • Re-Tain™ for Mastitis
    • CMT for Mastitis
  • Sales & Distributors
  • Resources
  • News
  • Investors
  • About ImmuCell
    • About ImmuCell
    • Our Purpose
    • Management and Directors
    • Career Opportunities
    • Contact Us
  • First Defense
    • Tri-Shield First Defense®
    • Manufacturing Facility Expansion
    • Manufacturing Facility Virtual Tour
    • Testimonials
  • Re-Tain
    • Re-Tain™ for Mastitis
    • CMT for Mastitis
  • Sales & Distributors
  • Resources
  • News
  • Investors

STOCK QUOTE

PRESS RELEASES

Recent News | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014

SEC FILINGS
SEC FIlings

XBRL Documents

Annual Report and Proxy
CORPORATE GOVERNANCE
ICCC Code of Conduct

Charter and Powers of the Audit Committee

Nominating Committee Charter

Management & Directors

2018 Press Releases

Recent News  |  2021  |  2020  |  2019  |  2018  |  2017  |  2016  |  2015  |  2014

12-11-18 ImmuCell Announces USDA Approval of Dual-Force™ First Defense®

11-13-18 ImmuCell Announces Financial Results for Third Quarter of 2018

11-08-18 ImmuCell to Participate at 9th Annual Craig-Hallum Alpha Select Conference

11-07-18 ImmuCell to Announce Financial Results for Third Quarter of 2018

09-25-18 ImmuCell Announces Issuance of Human Food Safety Technical Section Complete Letter for its Purified Nisin Product

08-13-18 ImmuCell Announces Financial Results for Second Quarter of 2018

08-07-18 ImmuCell to Announce Financial Results for Second Quarter of 2018

08-07-18 ImmuCell Hires Senior Director of Quality

07-25-18 ImmuCell Announces Sale of Certain Non-Core Assets

07-10-18 ImmuCell Announces Preliminary Sales Results for Second Quarter of 2018

06-25-18 ImmuCell to Join Russell Microcap Index

05-14-18 ImmuCell Announces Financial Results for First Quarter of 2018

05-07-18 ImmuCell to Announce Financial Results for First Quarter of 2018

02-08-18 ImmuCell Announces Preliminary Financial Results for Fourth Quarter and Full Year 2017

02-06-18 ImmuCell to Announce Financial Results for Fourth Quarter and Full Year 2017

01-30-18 ImmuCell Appoints Two New Members to its Board of Directors

COMPANY CONTACT

Michael F. Brigham
President & CEO
mail@immucell.com
207.878.2770

INVESTOR CONTACT
Lytham Partners, LLC
iccc@lythampartners.com
602.889.9700

Contact Us

56 Evergreen Drive
Portland, ME 04103

Office: 207.878.2770

Sales: 1.800.IMMUCELL

mail@immucell.com

NASDAQ: ICCC

Privacy Policy
Terms of Use

Recent News

02-21-23 ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2022

02-15-23 ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2022

01-09-23 ImmuCell Announces Preliminary, Unaudited Sales Results for the Year Ended December 31, 2022

Follow Us

Find us on:

Facebook page opens in new windowYouTube page opens in new window
Copyright © 2020 ImmuCell Corporation
  • Home
  • About ImmuCell
  • First Defense
  • Re-Tain
  • Sales & Distributors
  • Resources
  • News
  • Investors
  • Contact Us
Footer Menu
Go to Top